Delayed time to emergency hip surgery in patients taking oral anticoagulants.


Journal

Thrombosis research
ISSN: 1879-2472
Titre abrégé: Thromb Res
Pays: United States
ID NLM: 0326377

Informations de publication

Date de publication:
Dec 2019
Historique:
received: 29 07 2019
revised: 04 11 2019
accepted: 06 11 2019
pubmed: 14 11 2019
medline: 6 5 2020
entrez: 14 11 2019
Statut: ppublish

Résumé

Surgical intervention within 48 h of admission in patients with acute hip fractures has been associated to lower morbidity and mortality. Patients anticoagulated with vitamin K antagonists (VKAs) have longer time to corrective surgery than those not anticoagulated. Sparse data exists on time to surgery (TTS) in patients taking direct oral anticoagulants (DOACs). The aim of this study is to establish TTS among non-anticoagulated and anticoagulated patients taking either VKA or DOAC. We conducted a retrospective cohort study of consecutive patients admitted with acute hip fracture between July 1, 2016 and December 31, 2017. Patient-, anticoagulant- and surgery-related characteristics were collected. The primary outcome was TTS calculated from time of admission. Median TTS with interquartile range (IQR) was compared among 3 groups of patients: DOAC, VKA and No OAC. A total of 472 patients were included: 12.5% (59/472) were anticoagulated (28/472 on VKAs and 31/472 on DOACs). Median TTS was longer in the VKA group [64 h (IQR: 50-84)] and in the DOAC group [(61 h; IQR: 42 to 77)] versus the No OAC group [44 h (IQR: 28-63), p = 0.0006 and p = 0.003 respectively]. There was no significant difference in median TTS in the VKA group versus the DOAC group (p = 0.6396). Patients taking either VKA or DOAC have significant delays to emergency hip fracture surgery compared to those not anticoagulated. Future studies aimed at examining this relationship more closely are warranted. In the meantime, an action plan aimed at early identification and appropriate management of anticoagulation in this vulnerable group of patients is necessary.

Identifiants

pubmed: 31722273
pii: S0049-3848(19)30482-7
doi: 10.1016/j.thromres.2019.11.005
pii:
doi:

Substances chimiques

Anticoagulants 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

110-114

Commentaires et corrections

Type : ErratumIn

Informations de copyright

Copyright © 2019 Elsevier Ltd. All rights reserved.

Auteurs

Teresa Cafaro (T)

Department of Medicine, University of Montreal, QC, Canada.

Camille Simard (C)

Department of Medicine, McGill University, Montreal, QC, Canada.

Vicky Tagalakis (V)

Division of Internal Medicine, Jewish General Hospital, McGill University, Montreal, QC, Canada; Center for Clinical Epidemiology and Community Studies, Lady Davis Institute, Jewish General Hospital, Montreal, QC, Canada; Department of Medicine, Jewish General Hospital, McGill University, Montreal, QC, Canada.

Maral Koolian (M)

Division of Internal Medicine, Jewish General Hospital, McGill University, Montreal, QC, Canada; Department of Medicine, Jewish General Hospital, McGill University, Montreal, QC, Canada. Electronic address: maral.koolian@mcgill.ca.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH